Sanofi SA, in collaboration with Regeneron Pharmaceuticals, Inc., has announced the results of the EVEREST phase 4 clinical study involving Dupixent (dupilumab) for the treatment of severe chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting asthma. The study demonstrated that Dupixent outperformed Xolair (omalizumab) across all primary and secondary efficacy endpoints related to CRSwNP and asthma. Key findings included a 1.60-point reduction in nasal polyp size and an 8.0-point improvement in the ability to identify different smells. These results were presented at the 2025 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress in Glasgow, UK. The study involved 360 adult participants and highlighted Dupixent's efficacy in targeting IL-4 and IL-13, significant drivers of type 2 inflammation.